Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
The J&J-Auris tie-up will yield a huge return for investors who went in big.